ERBB2 and breast carcinoma: For HER2-positive breast cancer, the use of adjuvant trastuzumab has been shown to improve disease-free survival (DFS) and overall survival (OS) when added to standard chemotherapy (Romond et al. 2005; Slamon et al. 2011).